SCHEMBL4787166

SCHEMBL4787166

Cn1nc(Nc2cccc(Cl)c2)c2cc(-n3cccn3)ccc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
MAPT P10636 3/20 0.43
KDM4E B2RXH2 3/20 0.43
HPGD P15428 2/20 0.43
HSD17B10 Q99714 2/20 0.43
CYP1A2 P05177 1/20 0.43
POLB P06746 1/20 0.43
HSP90AA1 P07900 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
MAPK1 P28482 1/20 0.43
CYP2C19 P33261 1/20 0.43
PIK3CA P42336 1/20 0.41
MTOR P42345 1/20 0.41
JAK3 P52333 1/20 0.41
NTRK2 Q16620 1/20 0.41
CAMK2A Q9UQM7 1/20 0.41
NOTUM Q6P988 1/20 0.41
KDM4C Q9H3R0 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4804196 0.84 MAPT (0.44) MEN1KMT2AMAPTKDM4EHPGD
SCHEMBL4786271 0.83 MAPT (0.44) MEN1KMT2AMAPTKDM4EHPGD
SCHEMBL4740878 0.82 EGFR (0.51) MEN1KMT2AMAPTKDM4EHPGD
SCHEMBL4787437 0.82 MAPT (0.43) MEN1KMT2AMAPTKDM4EHPGD
SCHEMBL4785974 0.78 FADS1 (0.55) MEN1KMT2AMAPTKDM4EHPGD
SCHEMBL4740887 0.78 MEN1 (0.56) MEN1KMT2AMAPTKDM4EHPGD
SCHEMBL4786745 0.77 GAA (0.53) MEN1KMT2AMAPTKDM4EHPGD
SCHEMBL4809954 0.77 FADS1 (0.66) MEN1KMT2AMAPTCYP1A2CYP3A4
SCHEMBL4742065 0.76 FADS1 (0.59) MEN1KMT2AMAPTKDM4EHPGD
SCHEMBL4739653 0.76 MEN1 (0.45) MEN1KMT2AMAPTKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008089310-A2 DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY LEXICON PHARMACEUTICALS, INC. (US) 2008-07-24 WO claimed
WO-2008089307-A2 DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER LEXICON PHARMACEUTICALS, INC. (US) 2008-07-24 WO claimed
US-20080200458-A1 Methods and compositions for the treatment of body composition disorders LEXICON PHARMACEUTICALS, INC. 2008-08-21 US disclosed
US-20080194557-A1 Methods and compositions for the treatment of pain, inflammation and cancer LEXICON PHARMACEUTICALS, INC. 2008-08-14 US disclosed
WO-2008089310-A2 DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY LEXICON PHARMACEUTICALS, INC. (US) 2008-07-24 WO disclosed
WO-2008089307-A2 DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER LEXICON PHARMACEUTICALS, INC. (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194557-A1 Methods and compositions for the treatment of pain, inflammation and cancer TNF, IL6, CXCL8 MEN1 3245/4885KMT2A 3920/4885MAPT 1069/4885
US-20080200458-A1 Methods and compositions for the treatment of body composition disorders CPT1B, CPT1A, SHBG MEN1 1919/4885KMT2A 3148/4885MAPT 2635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.